- Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
-
Zang R, Zhu J
- KMID: 2458912
- J Gynecol Oncol.
- 2019 Nov;30(6):e116.
- doi: 10.3802/jgo.2019.30.e116
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- The 5th Shanghai Gynecologic Oncology Group (SGOG)-Korean Gynecologic Oncology Group (KGOG) joint meeting and 2016 Asia-Pacific Ovarian cancer Laparotomy and Laparoscopic Operation (APOLLO) symposium in Shanghai
-
Chang HK, Kim BG, Shi TY, Zang R
- KMID: 2374265
- J Gynecol Oncol.
- 2016 Nov;27(6):e64.
- doi: 10.3802/jgo.2016.27.e64
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
-
Shi T, Xiang L, Zhu J, Liu J, Zhang P, Wang H, Feng Y, Zhu T, Zhang Y, Yu A, Jiang W, Wang X, Zhu Y, Wu S, Teng Y, Zhang J, Jiang R, Zhang W, Jia H, Zang R
- KMID: 2537900
- J Gynecol Oncol.
- 2022 Jul;33(4):e63.
- doi: 10.3802/jgo.2022.33.e63
-
- CITED
-
- Close
- SHARE
-
- Close
- Association of High Expression of Mitochondrial Fission Regulator 2 with Poor Survival of Patients with Esophageal Squamous Cell Carcinoma
-
Li H, Zhu X, Zhang W, Lu W, Liu C, Ma J, Zang R, Song Y
- KMID: 2524119
- J Cancer Prev.
- 2021 Dec;26(4):250-257.
- doi: 10.15430/JCP.2021.26.4.250
Mitochondrial fission regulator 2 (MTFR2) is associated with mitochondrial fission, while few studies have assessed the associations between MTFR2 expression and clinical characteristics or prognosis of esophageal squamous cell carcinoma... -
- CITED
-
- Close
- SHARE
-
- Close
- Current status of gynecological cancer in China
-
Kim K, Zang R, Choi SC, Ryu SY, Kim JW
- KMID: 2245084
- J Gynecol Oncol.
- 2009 Jun;20(2):72-76.
- doi: 10.3802/jgo.2009.20.2.72
The aim of this review is to examine the current status of gynecological cancer in China focusing on epidemiological data. Epidemiological data on gynecological cancer in China is sparse. Therefore,... -
- CITED
-
- Close
- SHARE
-
- Close
- A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
-
Shi T, Yin S, Zhu J, Zhang P, Liu J, Xiang L, Zhu Y, Wu S, Chen X, Wang X, Teng Y, Zhu T, Yu A, Zhang Y, Feng Y, Huang H, Bao W, Li Y, Jiang W, Zhang P, Li J, Ai Z, Zhang W, Jia H, Zhang Y, Jiang R, Zhang J, Gao W, Luan Y, Zang R
- KMID: 2500489
- J Gynecol Oncol.
- 2020 Apr;31(3):e61.
- doi: 10.3802/jgo.2020.31.e61
Background: In China, secondary cytoreductive surgery (SCR) has been widely used in ovarian cancer (OC) over the past two decades. Although Gynecologic Oncology Group-0213 trial did not show its overall... -
- CITED
-
- Close
- SHARE
-
- Close
- Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept
-
Jiang R, Zhu J, Kim JW, Liu J, Kato K, Kim HS, Zhang Y, Zhang P, Zhu T, Aoki D, Yu A, Chen X, Wang X, Zhu D, Zhang W, Jia H, Shi T, Gao W, Yin S, Feng Y, Xiang L, Okamoto A, Zang R
- KMID: 2511991
- J Gynecol Oncol.
- 2020 Sep;31(5):e86.
- doi: 10.3802/jgo.2020.31.e86
Background: Two randomized phase III trials (EORTC55971 and CHORUS) showed similar progression-free and overall survival in primary or interval debulking surgery in ovarian cancer, however both studies had limitations with... -
- CITED
-
- Close
- SHARE
-
- Close
